1. In women with hypertension I-II stage, 1-2 degrees under the age of 65 years, antihypertensive therapy, regardless of the group of drugs used leads to a more likely decrease in brachial systolic, diastolic and mean hemodynamic blood pressure (respectively 13.3%, 18.9 %, 8.1%) compared with men of the appropriate age.
2. Antihypertensive therapy with the use of calcium channel blockers in comparison with the group of inhibitors of the renin-angiotensin system led to a decrease in central blood pressure (CBP), pulse (PBP), mid. BP and a significant decrease in arterial stiffness in patients with stage I – II hypertension, 1-2 years younger than 65 years compared with men, which was associated with regression of left ventricular hypertrophy (decrease in LV BMI by 9.3%) only in men who gives grounds to recommend it as a group of first-line therapy in this category of patients.
3. In patients with stage I – II hypertension, 1-2 degrees over the age of 65 years, regardless of gender, amlodipine / indapamide-retard combination antihypertensive therapy is more effective than ACE inhibitors / ARBs with indapamide: reduced bSBP (18.4 % vs. 13.9%), cSBP (16.9% vs. 11.4%), cPBP (27.4% vs. 16.2%), which is combined with a more pronounced decrease in arterial stiffness in terms of AIx75 (16.9%) against 9.7%) and AR (26.7% vs. 11.2%), regression of LVH (12.8% vs. 1.8%) and can be recommended as a priority in elderly patients.
4. Increased arterial stiffness according to aplanation tonometry in women older than 65 years with hypertension is associated with decreased vitamin D and secondary hyperparathyroidism, increased levels of markers of bone resorption, which may indicate the presence of common pathogenetic mechanisms of atherocalcinosis, increased stiffness and the feasibility of early screening of these indicators in order to correct the identified violations.
5. Application of the developed algorithm of complex examination of women older than 65 years with uncomplicated hypertension and addition to the combined antihypertensive and hypolipidemic therapy of vitamin D and ossein-hydroxyapatite compounds for 6 months is effective in the correction of arterial stiffness and lack of tissue metabolism. as evidenced by a decrease in augmentation pressure (33.1% vs. 18.6%), augmentation index (21.6% vs. 11.4%) and an increase in amplification pressure (11.2% vs. 6.8%, respectively), which is associated with normalization of vitamin D, parathyroid hormone, reduction of the level of the absorption marker β – CTx (by 21.1%), improvement of BMD of the cervical femur (by 8.7%) and can be recommended in the complex therapy of this category of patients.
